Clinical Trial Update: A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease [Phase 3]

View source ↗

Summary

A follow-on safety study in Crohn's disease patients previously withdrawn from a double-blind study due to Crohn's exacerbation; Phase 3 completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CDP870 (certolizumab pegol)

Snippet

Sponsor: UCB Pharma SA | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-07-04